Separately, Zacks Investment Research raised Second Sight Medical Products from a hold rating to a buy rating and set a $1.00 price target for the company in a report on Wednesday, November 20th.
Shares of NASDAQ:EYES opened at $0.86 on Tuesday. Second Sight Medical Products has a 1 year low of $0.63 and a 1 year high of $1.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.83 and a quick ratio of 2.66. The company’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $0.81.
About Second Sight Medical Products
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Read More: Quiet Period
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.